



CASPR Overview

The Coalition to Accelerate and Support Prevention Research

August 29, 2023

Stacey Hannah

Director of Research Engagement, AVAC

Project Director, CASPR

CASPR's Partner Network



Plus:


*African Women's Community Prevention Accountability Board
Africa Media Cafés (in Kenya, Malawi, Uganda, Zambia and Zimbabwe)
Africa free of New HIV infections (AfnHi) and Youth Cohort*

*APHA Ground Forces
Advocacy Fellows Network
LeNNiB Champions*

Who We Are, What We Do

- Strategic partnership of 13 organizations with ultimate goal of **supporting the development and sustainability of an Africa-centered network**
- Dedicated to accelerating biomedical HIV prevention research, and the introduction of and equitable access to a range of HIV prevention options
- Partners develop and implement advocacy action plans based on their organizational priorities and analyses of needs in their country/community
- 9 Africa-based organizations in 6 countries, driving CS engagement and key advocacy priorities
- 4 US/northern-based organizations working in solidarity and providing technical and strategic support
- AVAC is currently the prime (2016-2026) but with a commitment to transitioning leadership over the life of the project


CASPR's Guide: Biomedical Prevention Pipeline



¹In Oct 2019, US FDA approved F/TAF for adults and adolescents who have no HIV risk from receptive vaginal sex; still in development for cisgender women.


²Efficacy trials not required; bioequivalency of the two approved products when dosed together may be all that is required.

Biomedical Px Pipeline of Projects



Overview

Support development and sustainability of an Africa-centered network dedicated to advancing advocacy, policy, regulatory, community engagement, and communications efforts that accelerate biomedical HIV prevention research, development and delivery



Strategic Pillars


Objectives

- **Advocacy & Policy:** Strengthen and expand informed, action-oriented global advocacy and facilitate the development of policies and practices that support and facilitate the rapid, ethical development, introduction and use of new HIV prevention options
 - Domestic Resource Mobilization
 - African Women's Community Prevention Accountability Board
 - Engagement with the AU, Africa CDC
- **Research Translation:** Develop and/or strengthen systems and platforms for national, regional and global research findings into policies and practices to address HIV prevention as well as a research agenda that reflects the needs of African communities
 - African-led Media Cafes
 - PxPulse podcast
- **Research Preparedness:** Ensure that rights and interests of all stakeholders such as trial participants, event organizers, and community members are respected in the scientific, policy and programmatic processes
 - GPP Body of Evidence / Clearinghouse
 - Gilead's GCAG for PURPOSE (LEN)

Select Deliverables Over the Years

Domestic Resource Mobilization Learning Collaborative
An open community forum to discuss health R&D investment in Africa.

Zimbabwe AVAC Fellow Wins BIG
April 5, 2023 HealthTimes



Onward Chironda

WOMEN'S CHOICE FOR HIV PREVENTION AT RISK
"Find the money to fund the ring"
#FundTheRing #FacilitateChoice

Live WEBINAR
"WE CANNOT STOP NOW! WE MUST KEEP GOING"
FRIDAY 17th SEPTEMBER 2021 FROM 12pm-1pm E.A.T

OUR SPEAKERS

- JOYCE NGANGA
WACI Health, AINHi coordinator
- DR. KATHRYN MANGADI
WHIP TB Site PI and CRS Leader
Clinical Research Support,
Research Centre Tembisa
- NTANDO YOLA, DESMOND TUTU
Health Foundation and co-founder
of Advocates for Prevention of HIV in Africa.

An effective, affordable, accessible HIV vaccine

2021 BIOMEDICAL HIV PREVENTION FORUM
AN OFFICIAL PRE-CONFERENCE OF ICASA
6th DECEMBER 2021
12:25pm - 15:00pm (CAT)
Financing of HIV Prevention Research in Africa
HYBRID FORUM



NO DATA NO MORE
Manifesto to Align HIV Prevention Research with Trans and Gender-Diverse Realities
AVAC June 2021

Advancing HIV Prevention Research in Pregnant and Lactating People (PLP)
Think Tank Report & Action Plan
March 2023



Strengthening Stakeholder Engagement Through Ethics Review – HIV Prevention Trials
View Course details

JIAS
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
Science, theory, and practice of engaged research: Good Participatory Practice and beyond

AVAC
What We Do Prevention Options New

Changing minds: Journalists see a universe of genders

RLNZ
Research-to-Rollout Literacy Networking Zone
Global Village Booth 104

PxPulse
Research Fundamentals: What is an endpoint? (9:01)
December 13, 2021
Our PxPulse series, *Research Fundamentals*, explains key concepts in HIV prevention research. In this episode, host PxPulse host Jeanne Baron and Matthew Rose, a veteran HIV advocate and now Director at Global Health Strategies, look at endpoints in research.


THE AFRICA HEALTH R&D WEEK
A Continental Forum on Domestic Resource Mobilization for Health R&D in Africa

RESOURCE TRACKING FOR HIV PREVENTION RESEARCH & DEVELOPMENT
Investment by Technology Funding Trends Key Findings About


HIV Prevention Research & Development Investments
In its 16th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group

Year 7 Achievements: Select Activities and Results Linked to CASPR Key Priorities

CASPR partners are **leading voices** in the field that use **diverse platforms** to ensure HIV prevention science is **accessible, well-understood, supported, and community-centric.**



Advocating for Choice as the Prevention Landscape Evolves



Products that Made a Difference

More than a report, a webinar, a toolkit – CASPR products contribute to outcomes that advance and safeguard the field

The Choice Manifesto

Translating HIV Prevention Options into Choices – and Impact


Presented by: Yvette Raphael, APHA; Joyce Nganga, WACI Health; Navita Jain, AVAC – on behalf of the African Women Prevention Community Accountability Board (AWPCAB)

14 March 2023


Global PrEP Learning Network Webinar



The Choice Manifesto will serve as a call to action to center choice in decision-making around HIV prevention research and access



Fellow Natasha Mwila takes education on the Ring to TikTok, resulting in thousands of views and new audiences for dissemination of info on HIV prevention options



The first edition of the [Results Bulletin](#) was released, showcasing results and outcomes of CASPR partners through SPARC stories.

*“Recognizing also that stakeholder and community engagement and participation is an antidote to the mistrust that plagues public health; and helps build understanding of and trust in response measures, from initial public health measures to vaccines, therapeutics and diagnostics validated through clinical research conducted in accordance with **Good Participatory Practice (GPP)**, thereby improving community compliance with measures to prevent or control pandemics”.*

GPP language added to the Pandemic Prevention, Preparedness and Response HLM draft demonstrates reach of GPP as a best practice

Influencing Key Decision-makers

- Engagement with USAID, PEPFAR, UNAIDS leadership at AIDS 2022
- Engagement with ViiV around price transparency
- Development of the African Women's Community Prevention Accountability Forum
- Development of the Choice Manifesto
- Continued engagement with UNAIDS to be a champion of choice for women



The Choice Manifesto
Translating HIV Prevention Options into Choices – and Imp

Presented by: Yvette Raphael, APHA; Joyce Nganga, WACI Health; Navita Jain, AVAC
behalf of the African Women Prevention Community Accountability Board (AWPCA)
14 March 2023
Global PrEP Learning Network Webinar



CAB for PrEP: Much Achieved, Much to Do

With sustained advocacy and engagement, CASPR partners contributed to wins for access, pricing, and transparency; but there is still more to do

ACTIONS

Statement by Southern African women advocates to ViiV demanding meaningful engagement and price transparency

Continued pressure from advocates on price transparency and access

Published *Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access & Introduction of Injectable CAB for PrEP*

Advocates at AIDS 2022 use the moment to protest ViiV's lack of transparency

Coalition shared letter and follow-up call with CEO advocating key points on supply chain transparency

First meeting of MPP CAP

Updated Coalition to Accelerate Access to LA PrEP structure; engagement of CS Caucus, including outreach to PEPFAR & GF

Jan 2022

Apr 2022

July 2022

Sept 2022

Jan 2023

Apr 2023

OUTCOMES

ViiV engages with advocates, including information-sharing and creation of a formal engagement mechanism (Accountability Board)

ViiV revises strategy and publicly announces openness to a voluntary license with MPP

Voluntary license between ViiV and MPP finalized

ViiV steps down from leading PrEP-ACT VL Coalition; new Coalition formed with AVAC as Secretariat

AVAC & CASPR partners have formal role on MPP CAP to push on cost and access; ViiV commitment on better transparency

MPP announces 3 sub-licenses for generic manufacturing

PEPFAR/GF commitments to buy minimally available product volume to further push ViiV on increasing volume

ViiV, PEPFAR, GF articulate CAB strategy with Coalition

CS input included in IS study and guidance docs, (e.g. Zambia Implementation Framework on CAB for PrEP)

Ensuring Prevention Product Development Reflects Needs of Those Most Affected



SA Consultation on bNAbs for Infant Prophylaxis (IAVI, Feb 2023): Concerns from Advocates

- 15-25 minutes bNAb administering/injection time
- Progression of infant efficacy trials on the basis of safety data from Phase 1 trials in adults - researchers have very limited safety and tolerability data of combination bNABs in infants
- bNAb product profile needs to have a long half-life to reduce the number of administrations needed during breastfeeding - need for researchers to develop longer-acting bNAbs – that last over 6 months or more.
- Could existing (CAB-LA) & up-coming (LEN) long-acting ARV-based prevention modalities be better options for post-natal prevention/prophylaxis?
- Over-promising: bNAbs positioned as cheaper, affordable and a technology that can be easily manufactured in-sub-Saharan Africa

bNAb Product Development

Ongoing and active engagement, literacy, and advocacy efforts around bNAb use-case, trial design, and future access

- **bNAb literacy** building with researchers, developing a cadre of informed advocates
- **HIV Vaccine Awareness Day webinar on [bNAbs](#)** (with additional webinar on [mRNA technology](#))
- Engagement at **HVTN and HPTN** network meetings
- **Three new resources on [mRNA trials](#), [EMVTs](#), [antibodies](#)**; and a preview of the “Lab to Jab” advocates brief
- Serve as advocacy reps on IAVI’s task force to advance bNAbs for peri/postnatal prophylaxis, through APHA

**HIV VACCINE
AWARENESS DAY** MAY 18
2023



“The scientific complexities of bNAbs require a more attuned focus on community engagement... And it will require a high degree of validating [people’s] lived experience.”

— Khadija Richards, Wits RHI

JIAS | JOURNAL OF THE
INTERNATIONAL AIDS SOCIETY Open Access 

VIEWPOINT |  Open Access |  

Antibodies for HIV prevention: the path forward

Shelly Malhotra ✉ Rachel Baggaley, Sharonann Lynch, Carmen Pérez-Casas, Yvette Raphael, Lynda Stranix-Chibanda

First published: 17 May 2023 | <https://doi.org/10.1002/jia2.26097>

☰ SECTIONS

 PDF  TOOLS  SHARE


The lack of accountability in defining a timely pathway for equitable access to and scale-up of medical innovations has led to scepticism among key constituencies about the value of investing and participating in HIV prevention research. Communities are tired of promises of improved prevention options that do not materialize for those most in need.

Ensuring Young Women Have an Impactful Role – Young Women’s HIV Prevention Council




Role of Advocates as Advisors in Clinical Trials

CASPR provides technical expertise on clinical trials from research to rollout, participating in global, regional and national community advisory groups and creating new, independent advisory and engagement mechanisms to influence the pipeline of HIV prevention research and introduction. CASPR provides feedback on protocols, plans for rollout and access, community acceptability and more.



Projects Represented on YWHPC



Thank You!

Coalition to Accelerate and Support Prevention Research (CASPR)



Cooperative Agreement No. AID-OAA-A-16-00031

HIV Vaccine and Biomedical Prevention Research Project—Objective 3



Extra Slides

Year 7 Priorities

Priority	Pillar 1: Advocacy Network & Policy Engagement	Pillar 2: Research Translation	Pillar 3: Research Preparedness
Maintain momentum for HIV vaccine research and development	Continue to advocate for the important role of vaccine research in the HIV response, amid the field's shift to more upstream and exploratory science. Engage with advocates to support this agenda.	Develop strategies for engaging communities and civil society in early stage, experimental medicine and develop this research and v mean – for product	Continue to monitor Mosaico, and build capacity in the science and ethics of
CAB-LA introduction and access	Continue advocacy to ensure CAB for PrEP is available to all populations in need through engaging regulators, ministries, funders and other key decision makers; continue to press ViiV for transparency and accountability on pricing and production. Represent civil society and advocacy perspectives on key working groups and steering committee of LA-PrEP Coalition.	Update and supplement key issues access: testing, reg and manufacturing protocols for implementation implications of sub-introduction.	Programmatic Scope APHA ensures accountability for policy, investment and leadership in the HIV response, and leads key engagement mechanisms, including the National Stakeholder Engagement Forum and the Accountability Board. APHA's flagship program is its Ground Forces—a program through which APHA mentors young women prevention advocates around HIV prevention and sexual and reproductive health. AVAC is the prime grantee for CASPR and works with all partners across the three Strategic Pillars to contribute to the overarching project goal of developing a sustainable Africa-led network to accelerate HIV prevention research and equitable access to and introduction of HIV prevention products. AVAC also ensures strategic linkages to other USAID-supported projects (e.g., MOSAIC and MATRIX) as well as Gates-funded (BioPIC and COMPASS) and CIFF-funded (Dual Prevention Pill Consortium) projects, and the Global HIV Prevention Coalition to maximize efficiency and leverage across the HIV prevention research landscape.
Dapivirine Vaginal Ring introduction and access	Support advocates to hold accountable country policy makers and donors for making DVR available, including regulatory review processes, national guideline development and resource mobilization. Continue to reinforce young women's interest in and need for options for HIV prevention.	Expand awareness stakeholders and if women's options of implementation implications for ring	Partner Advocates for the Prevention of HIV and AIDS (APHA) AVAC Copper Rose Zambia (CRZ) FHI 360 The HIV AIDS Vaccines Ethics Group (HAVEG)
Next-generation ARV, vaccine and bNAb pipelines	Support and track confidence in research processes and decision-making among communities; incorporate CS perspectives into TPP and other policy-focused discussions, especially with focus on access for LMICs; help ensure stakeholder support for the broad pipeline.	Focus research like experimental trials, concepts and study stakeholders are a and supporting the	Geographic Scope South Africa Global, with a focus in East and Southern Africa Zambia Global South Africa
Next-gen PrEP efficacy trials	Advance clear and specific messages around programming for choice, including the need to develop next-gen PrEP products. Draw on actions from the Think Tank to Advance Inclusion of PLP in HIV Prevention Research to influence next-gen PrEP efficacy trial conduct and population priorities.	Complement resea next-generation tri landscape for stan	Programmatic Scope CRZ is a youth-led family planning organization brought on to respond to the SRH and youth engagement needs of the Coalition. CRZ will co-convene an advocacy workshop on SRH and build HIV prevention research literacy in its youth network. FHI 360 brings its GPP expertise to conversations on gender and research in pregnant and lactating people, and is developing a GPP M&E theory of change. HAVEG leverages its expertise in research ethics to enhance the REC/ IRB review of stakeholder engagement practices in HIV vaccine trial protocols and implementation. HAVEG continues to implement the Strengthening Engagement Through Research Ethics (SETER) Course and addresses ethics considerations for special populations in research (e.g. AGYW, PLP). IAVI supports science literacy and advocacy, linked with the IAVI Clinical Research Centers and the USAID-funded ADVANCE program. IAVI builds collaborations between East Africa and India to share and influence research priorities, implement national strategies around domestic financing for health R&D, and build capacity of key population groups on advocacy and policy. Internews builds media and civil society capacity to disseminate credible and actionable information to specific target audiences in HIV/AIDS prevention and treatment. Internews provides training and capacity building to journalists in HIV prevention and research and supports CASPR partners to strengthen their engagements with the media.
Advance advocacy and literacy around MPTs and SRH integration	Expand strategic collaborations established during ECHO in support of an integrated SRH research and advocacy agenda, and engage in national technical working groups supporting SRH integration.	Build literacy arou	Partner New HIV Vaccine and Microbicide Advocacy Society (NHVMAS) Pangaea Zimbabwe AIDS Trust (PZAT) The Treatment and Advocacy Literacy Campaign (TALC) Uganda Network of AIDS Service Organizations (UNASO)

Year 7 Priorities

Just an example of what a slide could look like for slide 11 if we wanted to make it readable

Priority	Pillar 1: Advocacy Network & Policy Engagement	Pillar 2: Research Translation	Pillar 3: Research Preparedness
Maintain momentum for HIV vaccine R&D	Advocate role of vaccine R&D with shift upstream	Engaging communities and civil society in early stage, experimental medicine studies	Manage Mosaico result, and build capacity in science and ethics of experimental medicine trials
CAB-LA introduction and access	Continue advocacy to ensure CAB for PrEP is available to all populations in need through engaging regulators, ministries, funders and other key decision makers; continue to press ViiV for transparency and accountability on pricing and production. Represent civil society and advocacy perspectives on key working groups and steering committee of LA-PrEP Coalition.	Update and supplement materials/tools that convey key issues related to introduction and access: testing, regulatory, voluntary licensing and manufacturing. Ensure ongoing plans and protocols for implementation research implications of sub-study results are translated for introduction.	Engage with key efforts on CAB for PrEP – including the CAB/LA-PrEP Coalition, MOSAIC, BioPIC – to ensure that civil society and advocacy perspectives inform implementation science approaches. Ensure Good Participatory Practice in the design of implementation studies.
Dapivirine Vaginal Ring introduction and access	Support advocates to hold accountable country policy makers and donors for making DVR available, including regulatory review processes, national guideline development and resource mobilization. Continue to reinforce young women’s interest in and need for options for HIV prevention.	Expand awareness of DVR among key stakeholders and its potential for increasing women’s options for HIV prevention. Stay abreast of implementation study developments and implications for ring availability and access.	Track impact of regulatory and donor decisions on 90-day ring, the dual-purpose ring and other MPTs.
Next-generation ARV, vaccine and bNAb pipelines	Support and track confidence in research processes and decision-making among communities; incorporate CS perspectives into TPP and other policy-focused discussions, especially with focus on access for LMICs; help ensure stakeholder support for the broad pipeline.	Focus research literacy efforts on upstream and experimental trials, as well as new scientific concepts and study designs to ensure that stakeholders are aware, aligned, engaged with and supporting the pipeline.	Consider stakeholder engagement processes, trial design, standard of care and ethical implications of “upstream” research. Map the pipelines and track relevant early-phase trials and products.
Next-gen PrEP efficacy trials	Advance clear and specific messages around programming for choice, including the need to develop next-gen PrEP products. Draw on actions from the Think Tank to Advance Inclusion of PLP in HIV Prevention Research to influence next-gen PrEP	Complement research literacy efforts around next-generation trial design; articulate changing landscape for standard of prevention.	Continue to support national & regional advocates’ engagement mechanisms for the PURPOSE trial (Gilead’s Descovy and Lenacapavir), especially around future access planning

Core Partners

I think this is too org focused and not enough about the network – would rather focus on the work that is done; think we have this covered in slide 11, 12, but here just in case

Partner	Location	Focal Areas of work
Advocacy for Prevention of HIV and AIDS (APHA)	South Africa	Lead of Accountability Board focused on choice for women, national policy engagement through TWGs, mentorship with youth through APHA Ground Forces; engagement with pharma around next-gen PrEP trials
AVAC	US	Suite of research literacy/translation resources, GPP trainings, advocacy mentorship programs (e.g. AVAC Advocacy Fellows), technical assistance
Copper Rose Zambia	Zambia	Sexual and reproductive health, youth advocacy capacity building, family planning
FHI 360	US	GPP Theory of Change; Gender Analysis; inclusion of PLP in research
HIV/AIDS Vaccine Ethics Group (HAVEG)	South Africa	Strengthening Engagement through Ethics Review (SETER) Course; SETER Study; site staff engagement in support of participatory engagement practices; inclusion of adolescents and PLP in research
International AIDS Vaccine Initiative (IAVI)	Kenya / India	Civil society budget advocacy trainings; vaccine/bNAb advocacy and research literacy; DRM
Internews	South Africa / Regional	Media Café Program; journalist trainings and training of trainers; engagement with media editors

Though not core partners, the CASPR network includes local Media Café conveners, AVAC Advocacy Fellows, and more!

CASPR Core Partners

Partner	Location	Focal Areas of Work
New HIV Vaccine and Microbicide Advocacy Society (NHVMAS)	Nigeria	Support and expand the HIV Prevention Coalition; CSO Accountability Forum; LeNNiB Champions Program
Pangea Zimbabwe AIDS Trust (PZAT)	Zimbabwe	MERL; vaccine confidence; inclusion of PLP in research; SRH integration
Treatment Advocacy and Literacy Campaign (TALC)	Zambia	Dapivirine Vaginal Ring (DVR) and CAB for PrEP advocacy/literacy; GPP trainings; Youth CAB; DRM
Uganda Network of AIDS Service Organizations (UNASO)	Uganda	Resource tracking; Uganda Cross-CAB meetings; DVR introduction; involvement of adolescents in research
WACI Health / Africa free of New HIV infections (AfNHi)	Kenya / Regional	(WACI is secretariat of AfNHi) AfNHi Youth Cohort; DRM policy; DVR introduction; vaccine advocacy and literacy
Wits Reproductive Health and HIV Institute (WRHI)	South Africa	GPP Leadership Course; GPP Community of Practice (CoP)

Though not core partners, the CASPR network includes local Media Café conveners, AVAC Advocacy Fellows, and more!